Company: SCLXW
Filing Date: 2025-05-15
Form Type: 424B3
Source: 0000950170-25-071914
Chunk: 74

Company: Scilex Holding Co
Filing Date: 2025-05-15
Form: 424B3
Chunk 74
---
 September 2023 in the principal amount of $101.9 million, of which the principal amount of $25.7 million remained outstanding as of March 31, 2025. The Tranche B Notes were issued in October 2024 in the principal amount of $50.0 million, of which the principal amount of $37.0 million remained outstanding as of March 31, 2025. Interest Expense, Net Interest expense, net for the three months ended March 31, 2025 and 2024 was $2.5 million and $0.5 million, respectively. Interest expense of $2.5 million for the three months ended March 31, 2025 primarily consists of the interest on the balances due for government and commercial rebate programs. Interest expense of $0.5 million for the three months ended March 31, 2024 consists of the interest related to the Revolving Facility. Liquidity and Capital Resources As of March 31, 2025, we had cash and cash equivalents of approximately $5.8 million. We have funded our operations primarily through the financing pursuant to the ATM Sales Agreement (as defined below). We also have indebtedness pursuant to the Oramed Note and Tranche B Notes as well as deferred consideration related to the GLOPERBA license acquired from Romeg in 2022. The following table summarizes the aggregate indebtedness of these issuances as of March 31, 2025 and December 31, 2024 (in thousands):

| Oramed Note (outstanding principal balance: $25.7 million and $25.0 million as of March 31, 2025 and December 31, 2024, respectively)     |     | March 31, 2025 | 14,962 |     | December 31, 2024 | 12,161 |
|:------------------------------------------------------------------------------------------------------------------------------------------|:----|:---------------|-------:|:----|:------------------|-------:|
| Tranche B Notes (outstanding principal balance: $37.0 million and $38.0 million as of March 31, 2025 and December 31, 2024, respectively) |     |                | 24,480 |     |                   | 23,560 |
| Purchased Revenue Liability                                                                                                               |     |                |  7,300 |     |                   |  6,800 |
| Deferred Consideration with Romeg                                                                                                         |     |